Journal of Pharmacology and Pharmacotherapeutics

: 2012  |  Volume : 3  |  Issue : 3  |  Page : 286-

Author's reply

Biswajit Dubashi, Ankit Jain 
 Department of Medical Oncology, JIPMER, Puducherry, India

Correspondence Address:
Biswajit Dubashi
Department of Medical Oncology, JIPMER, Puducherry - 605006

How to cite this article:
Dubashi B, Jain A. Author's reply.J Pharmacol Pharmacother 2012;3:286-286

How to cite this URL:
Dubashi B, Jain A. Author's reply. J Pharmacol Pharmacother [serial online] 2012 [cited 2022 Jan 24 ];3:286-286
Available from:

Full Text

L-Asparaginase is an important drug used in the induction phase of acute leukemia. A meta analysis of 17 prospective studies of 1752 paediatric Acute Lymphoblastic Leukaemia patients revealed the rate of thrombosis was 5.2%. [1] Our patient did not have any central line or co-morbidities which could have resulted in thrombosis. High-dose steroids are rarely associated with cortical venous thrombosis. It would be difficult to rule out the concomitant involvement of steroids in this case. The risk of thrombosis with steroids is higher with Prednisolone when compared to dexamathosone. [1] I do not think the cytogenetics, immunophenotype, or risk-adapted protocols would influence the risk of thrombosis. The association of genetic prothrombotic defects and thrombotic events is unclear. [1] A high index of suspicion is definitely required in the identification of l-asparaginase induced cortical venous thrombosis. Any patient presenting with headache, vomiting, and recurrent seizures during the induction phase should undergo early magnetic resonance imaging (MRI). Once the diagnosis is confirmed, l-asparaginase should be withdrawn from the treatment protocol immediately.


1Caruso V, Iacoviello L, Castelnuovo A, Storti S, Mariani G, de Gaetano G, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: A meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006;108:2216-22.